Sigyn Therapeutics (SIGY) Stock Overview

Sigyn Therapeutics, Inc. operates as a medical technology company, focuses on creating therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. It also developing ChemoPrep to enhance the tumor site delivery of chemotherapy; and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. The company is headquartered in San Diego, California.